Maxigen Biotech (TPE:1783) Retained Earnings: NT$317.8 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

TPE:1783 Maxigen Biotech Inc TPE:1783
87 GF Score
Price NT$40.50
GF Value NT$59.46
Valuation Significantly Undervalued
View Full Analysis

What is Maxigen Biotech Retained Earnings?

Maxigen Biotech TPE:1783 +1.38% 87 Retained Earnings is NT$317.8 Mil as of Mar. 2026. GuruFocus rates TPE:1783 with a GF Score™ of 87/100 and a GF Value™ of NT$59.46 (Significantly Undervalued).

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Maxigen Biotech's retained earnings for the quarter that ended in Mar. 2026 was NT$317.8 Mil.

Maxigen Biotech's quarterly retained earnings increased from Sep. 2025 (NT$181.4 Mil) to Dec. 2025 (NT$265.0 Mil) and increased from Dec. 2025 (NT$265.0 Mil) to Mar. 2026 (NT$317.8 Mil).

Maxigen Biotech's annual retained earnings increased from Dec. 2023 (NT$199.4 Mil) to Dec. 2024 (NT$216.5 Mil) and increased from Dec. 2024 (NT$216.5 Mil) to Dec. 2025 (NT$265.0 Mil).


Maxigen Biotech  (TPE:1783) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Maxigen Biotech Retained Earnings Historical Data

* Premium members only.

The historical data trend for Maxigen Biotech's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Maxigen Biotech Retained Earnings Chart

Maxigen Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Retained Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only 87.71 138.52 199.45 216.46 265.04

Maxigen Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 263.41 105.98 181.37 265.04 317.82
TPE:1783
87GF Score
Maxigen Biotech Inc TPE:1783
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Maxigen Biotech Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of NT$317.8 Mil mean?
Maxigen Biotech (TPE:1783) has a Retained Earnings of NT$317.8 Mil as of Mar. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on Maxigen Biotech and its competitors.
Is Maxigen Biotech's Retained Earnings too high?
Maxigen Biotech's current Retained Earnings is NT$317.8 Mil. Overall, Maxigen Biotech has a GF Score™ of 87/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Maxigen Biotech's Retained Earnings compare to ISRG and BDX?
Maxigen Biotech's Retained Earnings of NT$317.8 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Medical Devices & Instruments company?
A good Retained Earnings depends on the Medical Devices & Instruments industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Maxigen Biotech and its competitors. Maxigen Biotech's current Retained Earnings is NT$317.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Maxigen Biotech stock overvalued right now?
Based on GuruFocus' analysis, Maxigen Biotech (TPE:1783) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$59.46, compared to a current price of NT$40.50 — trading 31.9% below its estimated fair value. The current Retained Earnings is NT$317.8 Mil. Maxigen Biotech's overall GF Score™ is 87/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Maxigen Biotech (TPE:1783), the current Retained Earnings is NT$317.8 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Maxigen Biotech (TPE:1783) Overvalued in 2026?

Based on GuruFocus' analysis, Maxigen Biotech stock appears to be undervalued. The current stock price of NT$40.50 is trading 31.9% below its estimated GF Value™ of NT$59.46. GuruFocus considers Maxigen Biotech to be Significantly Undervalued.

Key valuation signals for TPE:1783:

  • Retained Earnings: NT$317.8 Mil
  • GF Value™: NT$59.46 vs. price of NT$40.50 (31.9% below fair value)
  • GF Score™: 87/100

No single metric tells the full story. See the TPE:1783 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Maxigen Biotech Business Description

Address No.88, Keji 1st Road, Guishan District, Taoyuan City, TWN, 333
Maxigen Biotech Inc is engaged in collagen purification, research and development, production and sales of implantable medical device, and production, manufacturing, wholesale and retail of cosmetics. The group had two reportable segments: the biomedical products segment and consumer products segment. Biomedical products segment is engaged in the manufacturing and sales of collagen and bone materials. The consumer products segment is involved in the manufacturing and sales of beauty care products. Geographically, it operates in Taiwan, America, Europe, Asia, and other countries, with the majority of the revenue deriving from Taiwan.
87GF Score

Get the complete analysis for TPE:1783

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$40.50
Price
NT$59.46
GF Value